Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 6/20 | 0.37 |
| ▸ | NCF1 | P14598 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 4/20 | 0.35 |
| ▸ | CA1 | P00915 | 4/20 | 0.35 |
| ▸ | CA4 | P22748 | 4/20 | 0.35 |
| ▸ | CA9 | Q16790 | 4/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | GLP1R | P43220 | 5/20 | 0.34 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.33 |
| ▸ | HTR1A | P08908 | 1/20 | 0.33 |
| ▸ | TLR2 | O60603 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | ENO1 | P06733 | 1/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.31 |
| ▸ | SLC9A3 | P48764 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13434054 | 0.97 | MEN1 (0.37) | MEN1KMT2ACA2NCF1CA12 | |
| SCHEMBL15150163 | 0.97 | MEN1 (0.37) | MEN1KMT2ACA2NCF1CA12 | |
| SCHEMBL24040332 | 0.93 | MEN1 (0.41) | MEN1KMT2ACA2NCF1CA12 | |
| SCHEMBL4283146 | 0.93 | MEN1 (0.41) | MEN1KMT2ACA2NCF1CA12 | |
| SCHEMBL20017289 | 0.89 | MEN1 (0.41) | MEN1KMT2ACA2NCF1CA12 | |
| SCHEMBL7951389 | 0.89 | MEN1 (0.41) | MEN1KMT2ACA2NCF1CA12 | |
| SCHEMBL25455878 | 0.88 | MEN1 (0.40) | MEN1KMT2ACA2NCF1CA12 | |
| SCHEMBL21172350 | 0.88 | MEN1 (0.38) | MEN1KMT2ACA2NCF1CA12 | |
| SCHEMBL1257485 | 0.86 | GLP1R (0.41) | MEN1KMT2ACA2NCF1CA12 | |
| SCHEMBL14001490 | 0.86 | MEN1 (0.38) | MEN1KMT2ACA2NCF1CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1765408-B1 | POLYPEPTIDE PROTRACTING TAGS COMPRISING A TETRAZOLE MOIETY | NOVO NORDISK AS (DK) | 2015-12-09 | — | — | EP | claimed |
| US-9061067-B2 | Polypeptide protracting tags | NOVO NORDISK A/S (DK) | 2015-06-23 | — | — | US | claimed |
| EP-2289560-B1 | POLYPEPTIDE PROTRACTING TAGS COMPRISING A TETRAZOLE MOIETY | NOVO NORDISK AS (DK) | 2015-04-22 | — | — | EP | claimed |
| US-20090111730-A1 | Polypeptide protracting tags | NOVO NORDISK A/S (DK) | 2009-04-30 | — | — | US | claimed |
| US-20230165932-A1 | PCSK9 ANTAGONIST COMPOUNDS | MERCK SHARP & DOHME LLC | 2023-06-01 | — | — | US | disclosed |
| US-20230144324-A1 | PCSK9 ANTAGONIST COMPOUNDS | MERCK SHARP & DOHME LLC | 2023-05-11 | — | — | US | disclosed |
| US-20210069288-A1 | PCSK9 ANTAGONIST COMPOUNDS | MERCK SHARP & DOHME LLC | 2021-03-11 | — | — | US | disclosed |
| WO-2019023295-A1 | FATTY ACID MODIFIED HUMAN EPIDERMAL GROWTH FACTOR | SAINT LOUIS UNIVERSITY (US) | 2019-01-31 | — | — | WO | disclosed |
| EP-1765408-B1 | POLYPEPTIDE PROTRACTING TAGS COMPRISING A TETRAZOLE MOIETY | NOVO NORDISK AS (DK) | 2015-12-09 | — | — | EP | disclosed |
| US-9061067-B2 | Polypeptide protracting tags | NOVO NORDISK A/S (DK) | 2015-06-23 | — | — | US | disclosed |
| EP-2289560-B1 | POLYPEPTIDE PROTRACTING TAGS COMPRISING A TETRAZOLE MOIETY | NOVO NORDISK AS (DK) | 2015-04-22 | — | — | EP | disclosed |
| WO-2012062803-A1 | DOUBLE-ACYLATED GLP-1 DERIVATIVES | NOVO NORDISK A/S (DK) | 2012-05-18 | — | — | WO | disclosed |
| US-20090111730-A1 | Polypeptide protracting tags | NOVO NORDISK A/S (DK) | 2009-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210069288-A1 | PCSK9 ANTAGONIST COMPOUNDS | PCSK9, PCSK7, PCSK6 | MEN1 1646/4885KMT2A 1433/4885CA2 3380/4885 |
| US-20230165932-A1 | PCSK9 ANTAGONIST COMPOUNDS | PCSK9, PCSK7, PCSK6 | MEN1 1646/4885KMT2A 1433/4885CA2 3380/4885 |
| US-20230144324-A1 | PCSK9 ANTAGONIST COMPOUNDS | PCSK9, PCSK7, PCSK6 | MEN1 969/4885KMT2A 1269/4885CA2 2725/4885 |
| US-20090111730-A1 | Polypeptide protracting tags | LNPEP, FGB, ENPEP | MEN1 3011/4885KMT2A 4689/4885CA2 4363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.